Lyra tops Sonoma on 7 of 11 comparison metrics

Lyra Therapeutics beat Sonoma Pharmaceuticals on 7 of 11 factors in a comparative stock article published Oct. 11 by Americanbankingnews, including institutional ownership of 95.6% versus Sonoma’s 1.9%.

The gap underscores different profiles among small-cap healthcare companies: Sonoma reported $19.53 million in gross revenue, almost 49 times Lyra’s $400,000, according to Atlas360 calculations.

The article cited MarketBeat data showing both companies had one sell rating, no hold ratings, no buy ratings and no strong-buy ratings. Each had a rating score of 1.00.

Ownership was the sharpest contrast. Company insiders held 1.0% of Sonoma shares and 3.3% of Lyra shares. Institutional ownership can show professional investor participation, though it does not establish future performance.

Volatility also diverged. Sonoma had a beta of 1.3, meaning its shares were listed as 30% more volatile than the S&P 500. Lyra’s beta was 0.5, described as 50% less volatile than the benchmark.

Sonoma showed a net margin of negative 10.33%, return on equity of negative 21.41% and return on assets of negative 6.08%. Return on equity measures profit or loss relative to shareholder capital. Lyra’s comparable profitability figures were listed as not available.

Both companies were loss-making in the comparison. Sonoma reported net income of negative $3.17 million and earnings per share of negative $1.22. Lyra reported net income of negative $28.92 million and earnings per share of negative $19.15.

Valuation comparisons were limited by those losses. Sonoma had a price-to-sales ratio of 0.30, which compares market value with revenue, and a price-to-earnings ratio of negative 1.01, which normally compares share price with profit per share. Lyra had a price-to-sales ratio of 0.84 and price-to-earnings ratio of negative 0.01.

Sonoma develops hypochlorous-acid products across wound care, dermatology, eye care, oral care and animal health. Lyra is a clinical-stage biotechnology company focused on ear, nose and throat diseases, with LYR-210 in a Phase III clinical trial for chronic rhinosinusitis.

Source: comparative stock article, Americanbankingnews, Oct. 11, 2026